<DOC>
	<DOCNO>NCT00003046</DOCNO>
	<brief_summary>RATIONALE : Interleukin-12 may kill tumor cell stimulate person 's white blood cell kill cancer cell . PURPOSE : Phase I trial study effectiveness interleukin-12 treating patient cancer abdomen .</brief_summary>
	<brief_title>Interleukin-12 Treating Patients With Cancer Abdomen</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose intraperitoneal interleukin-12 patient Mullerian carcinoma ( close accrual 8/23/01 ) , gastrointestinal carcinoma , peritoneal mesothelioma ( close accrual 8/23/01 ) . II . Determine qualitative quantitative toxicity reversibility toxicity regimen patient . OUTLINE : This dose-escalation , multicenter study . Patients receive intraperitoneal interleukin-12 30 minute weekly 4 week . Treatment repeat every 4 week 6 course absence unacceptable toxicity disease progression . Patients stable responsive disease may receive additional 6 course . Patients receive escalate dos intraperitoneal interleukin-12 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Once MTD establish , additional patient accrue receive interleukin-12 recommend dose . PROJECTED ACCRUAL : Approximately 20-40 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Anus Neoplasms</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Interleukin-12</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm Mullerian carcinoma ( ovarian epithelial peritoneal carcinoma ) ( close accrual 8/23/01 ) OR Gastrointestinal cancer abdominal carcinomatosis OR Peritoneal mesothelioma ( close accrual 8/23/01 ) Must receive adequate course platinumbased chemotherapy regimen ovarian cancer evidence intraabdominal disease Must receive adequate course fluorouracilbased treatment metastatic colon cancer Intact primary gastrointestinal tumor allow risk obstruction and/or bleed Abdominal lesion must less 10 cm Extraperitoneal lesion must less 2 cm No hepatic disease No clinically significant pleural effusion ( control pleurodesis allow ) No brain metastases No significant adhesion symptom obstruction PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 02 Life expectancy : Not specify Hematopoietic : Absolute granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9 g/dL ( transfusion allow ) Lymphocyte count least 800/mm3 Hepatic : See Disease Characteristics Bilirubin great 1.5 mg/dL SGOT SGPT less 2.5 time upper limit normal Albumin least 3.5 g/dL Hepatitis B C negative Renal : Creatinine great 1.5 mg/dL Cardiovascular : No significant heart disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Loss 10 % body weight 4 month period No overt autoimmune disease No active ulcer disease No prior inflammatory bowel disease ( e.g. , Crohn 's disease ulcerative colitis ) PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy Chemotherapy : At least 3 week since prior chemotherapy ( 6 week mitomycin nitrosoureas ) recover No concurrent chemotherapy Endocrine therapy : No chronic steroid therapy Radiotherapy : At least 3 month since prior localize radiotherapy ( e.g. , pelvic small field ) recover No radiotherapy whole abdomen No concurrent radiotherapy Surgery : Recovered prior surgery At least 3 week since prior major abdominal surgery At least 2 week since prior laparoscopy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>anal cancer</keyword>
	<keyword>carcinoma appendix</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>extrahepatic bile duct cancer</keyword>
	<keyword>gallbladder cancer</keyword>
	<keyword>gastric cancer</keyword>
	<keyword>gastrointestinal carcinoid tumor</keyword>
	<keyword>malignant mesothelioma</keyword>
	<keyword>pancreatic cancer</keyword>
	<keyword>small intestine cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage IV anal cancer</keyword>
	<keyword>recurrent anal cancer</keyword>
	<keyword>metastatic gastrointestinal carcinoid tumor</keyword>
	<keyword>recurrent gastrointestinal carcinoid tumor</keyword>
	<keyword>advanced malignant mesothelioma</keyword>
	<keyword>recurrent malignant mesothelioma</keyword>
	<keyword>small intestine adenocarcinoma</keyword>
	<keyword>unresectable gallbladder cancer</keyword>
	<keyword>recurrent gallbladder cancer</keyword>
	<keyword>unresectable extrahepatic bile duct cancer</keyword>
	<keyword>recurrent extrahepatic bile duct cancer</keyword>
	<keyword>recurrent small intestine cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>